Weekly Analysts’ Ratings Updates for Apogee Therapeutics (APGE)

A number of research firms have changed their ratings and price targets for Apogee Therapeutics (NASDAQ: APGE):

• 3/17/2026 – Apogee Therapeutics is now covered by Truist Financial Corporation. They set a “hold” rating and a $83.00 price target on the stock.
• 3/16/2026 – Apogee Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $137.00 price target on the stock.
• 3/3/2026 – Apogee Therapeutics had its price target raised by Wedbush from $90.00 to $95.00. They now have an “outperform” rating on the stock.
• 3/2/2026 – Apogee Therapeutics had its price target lowered by Royal Bank Of Canada from $83.00 to $82.00. They now have a “sector perform” rating on the stock.
• 2/2/2026 – Apogee Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $95.00 price target on the stock.
• 1/25/2026 – Apogee Therapeutics had its “buy” rating reaffirmed by Citigroup Inc..
• 1/22/2026 – Apogee Therapeutics was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $83.00 price target on the stock, up from $70.00.
• 1/21/2026 – Apogee Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity at Apogee Therapeutics

In other news, Director Fairmount Funds Management Llc sold 1,750,000 shares of the firm’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $76.30, for a total transaction of $133,525,000.00. Following the completion of the transaction, the director directly owned 298,647 shares in the company, valued at $22,786,766.10. This trade represents a 85.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $74.78, for a total value of $1,495,600.00. Following the completion of the sale, the chief executive officer directly owned 1,152,987 shares of the company’s stock, valued at $86,220,367.86. The trade was a 1.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 1,839,700 shares of company stock worth $140,118,083. Company insiders own 42.77% of the company’s stock.

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.